BO43936
14 Sep 2023
BO43936
NCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Cancer Type | Renal Cell Carcinoma |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2023-04-21 |
Anticipated End Date | 2026-03-31 |
Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
---|---|
Clinical Trial Coordinator | Sue Yeend |
Sue.Yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Annabel Smith |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs